Copenhagen - Delayed Quote DKK

Novo Nordisk A/S (NOVO-B.CO)

903.30 -9.60 (-1.05%)
At close: May 17 at 4:59 PM GMT+2
Currency in DKK All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
244,243,000.00
232,261,000.00
176,954,000.00
140,800,000.00
126,946,000.00
Cost of Revenue
37,499,000.00
35,765,000.00
28,448,000.00
23,658,000.00
20,932,000.00
Gross Profit
206,744,000.00
196,496,000.00
148,506,000.00
117,142,000.00
106,014,000.00
Operating Expense
97,331,000.00
93,922,000.00
73,697,000.00
58,498,000.00
51,888,000.00
Operating Income
109,413,000.00
102,574,000.00
74,809,000.00
58,644,000.00
54,126,000.00
Net Non Operating Interest Income Expense
672,000.00
330,000.00
-320,000.00
-180,000.00
-203,000.00
Other Income Expense
--
1,770,000.00
-5,427,000.00
616,000.00
-793,000.00
Pretax Income
111,855,000.00
104,674,000.00
69,062,000.00
59,080,000.00
53,130,000.00
Tax Provision
22,579,000.00
20,991,000.00
13,537,000.00
11,323,000.00
10,992,000.00
Net Income Common Stockholders
89,276,000.00
83,683,000.00
55,525,000.00
47,757,000.00
42,138,000.00
Diluted NI Available to Com Stockholders
89,276,000.00
83,683,000.00
55,525,000.00
47,757,000.00
42,138,000.00
Basic EPS
19.97
18.67
12.26
10.40
9.03
Diluted EPS
19.91
18.62
12.22
10.37
9.01
Basic Average Shares
4,472,900.00
4,482,800.00
4,530,600.00
4,593,200.00
4,667,800.00
Diluted Average Shares
4,484,125.00
4,494,800.00
4,544,600.00
4,606,200.00
4,680,000.00
Total Operating Income as Reported
109,413,000.00
102,574,000.00
74,809,000.00
58,644,000.00
54,126,000.00
Total Expenses
134,830,000.00
129,687,000.00
102,145,000.00
82,156,000.00
72,820,000.00
Net Income from Continuing & Discontinued Operation
89,276,000.00
83,683,000.00
55,525,000.00
47,757,000.00
42,138,000.00
Normalized Income
87,927,940.78
82,333,489.00
59,736,352.00
47,239,880.00
42,885,006.00
Interest Income
2,363,000.00
1,069,000.00
239,000.00
231,000.00
337,000.00
Interest Expense
1,494,000.00
542,000.00
378,000.00
289,000.00
390,000.00
Net Interest Income
672,000.00
330,000.00
-320,000.00
-180,000.00
-203,000.00
EBIT
113,349,000.00
105,216,000.00
69,440,000.00
59,369,000.00
53,520,000.00
EBITDA
123,957,000.00
114,629,000.00
76,802,000.00
65,394,000.00
59,273,000.00
Reconciled Cost of Revenue
37,499,000.00
35,765,000.00
28,448,000.00
23,658,000.00
20,932,000.00
Reconciled Depreciation
10,608,000.00
9,413,000.00
7,362,000.00
6,025,000.00
5,753,000.00
Net Income from Continuing Operation Net Minority Interest
89,276,000.00
83,683,000.00
55,525,000.00
47,757,000.00
42,138,000.00
Total Unusual Items Excluding Goodwill
1,689,000.00
1,689,000.00
-5,238,000.00
640,000.00
-942,000.00
Total Unusual Items
1,689,000.00
1,689,000.00
-5,238,000.00
640,000.00
-942,000.00
Normalized EBITDA
122,268,000.00
112,940,000.00
82,040,000.00
64,754,000.00
60,215,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
340,940.78
339,489.00
-1,026,648.00
122,880.00
-194,994.00
12/31/2020 - 1/6/2001

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BAVA.CO Bavarian Nordic A/S
178.75
+3.12%
 
ZEAL.CO Zealand Pharma A/S
600.00
-2.99%
 
GMAB.CO Genmab A/S
2,041.00
+0.74%
 
ALK-B.CO ALK-Abelló A/S
152.00
-2.50%
 
GUBRA.CO Gubra A/S
302.00
+1.00%
 
VKTX Viking Therapeutics, Inc.
67.00
-2.98%
 
EXPRS2.ST ExpreS2ion Biotech Holding AB (publ)
1.4080
-0.98%
 
GMAB Genmab A/S
29.98
+1.11%
 
HNSA.ST Hansa Biopharma AB (publ)
36.50
-3.03%
 
ACIU AC Immune SA
3.1800
-6.74%